Drug intelligence / Profile preview

naja naja atra venom

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Oral, Intravenous (antivenom Context)
01

Overview

**Naja naja atra venom** is the crude venom derived from the Chinese cobra (Naja atra, formerly Naja naja atra), a cobra species native to southern China and neighboring regions. The venom is a complex mixture of bioactive peptides and proteins, including **cardiotoxins**, **cobratoxin (neurotoxin alpha-cobratoxin)**, **cobra venom factor**, **phospholipase A2**, and other enzymatic/non-enzymatic proteins. Medically, the crude venom—or fractions of it—has been studied primarily in animal models for its **anti-inflammatory** and **immunomodulatory** effects. Notably, research in mice has shown that oral administration of naja naja atra venom can protect against manifestations of systemic lupus erythematosus by reducing proteinuria, attenuating lymphadenopathy, decreasing inflammatory cytokines (IL-6, TNF-alpha), and modulating immune complex deposition and organ pathology[1]. Some studies have also suggested a protective effect in models of nephropathy and rheumatoid arthritis[1]. However, as a crude venom, it is not an approved pharmaceutical drug but rather a biological mixture of investigational and traditional medicine interest.

Other names
Chinese cobra venomNaja atra venomTaiwan cobra venomcobra venom
02

Targets

CardiolipinC3Muscle-type nicotinic acetylcholine receptorIL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on naja naja atra venom.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on naja naja atra venom.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call